While its growth was overshadowed in 2025 by A.I., the biotech sector grew signifcantly and 2026 looks for the trend to ...

This little-known biotech could have a big hit on its hands with VK2735, a GLP-1 weight loss drug candidate.

New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry ...

Looking back on biotechnology stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including Incyte ...

XBI has nearly 50 points of upside to reach its previous all-time high, and 2026 biotech industry conditions may help it get ...

Biotech held steady in early 2026 as M&A buyouts and rotation from the Magnificent Seven lifted IBB relative strength—read ...

The Motley Fool reports that biotech stocks surged in 2025, driven by FDA approvals and a doubling of longevity investment to ...

Biotech stocks offer potential high returns from developing drugs and therapies. Investing in biotech involves risks, such as clinical failures and regulatory hurdles. Diversified investment options ...

Learning how to trade biotech stocks offers some of the most explosive profit opportunities in the entire market—but also some of its most punishing risks. Biotech stocks can double or triple ...

After several years of IPO drought in the biotech industry, the public market is picking up again. Will the trend keep going in 2026?

Now, it’s worth noting Stock Advisor’s total average return is 880 % — a market-crushing outperformance compared to 178% for ...